Stockscreener 앱 받기
2.76
9.52%
0.24
시간 외 거래:
2.76
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Brokers Offer Predictions for Editas Medicine Q3 Earnings - MarketBeat
Editas Medicine Bets On Next-Gen Gene Editing - Finimize
Statistical indicators supporting Editas Medicine Inc.’s strengthRate Hike & AI Driven Stock Reports - Newser
Using portfolio simulators with Editas Medicine Inc. includedJuly 2025 Sector Moves & Growth Focused Entry Reports - Newser
What drives Editas Medicine Inc.’s stock price2025 Top Gainers & Capital Efficient Trading Techniques - خودرو بانک
What are Editas Medicine Inc.’s technical support levelsJuly 2025 Outlook & High Return Stock Watch Alerts - خودرو بانک
Can Editas Medicine Inc. weather a recession2025 Year in Review & Verified Technical Signals - خودرو بانک
Is Editas Medicine Inc. a momentum stockJuly 2025 Recap & Accurate Intraday Trade Tips - خودرو بانک
Can Editas Medicine Inc. expand into new marketsWeekly Stock Report & Weekly Consistent Profit Watchlists - خودرو بانک
Predicting Editas Medicine Inc. trend using moving averages2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - Newser
Volatility Watch: Is Editas Medicine Inc. stock influenced by commodity prices2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Wells Fargo & Company Issues Positive Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - MarketBeat
Is Editas Medicine Inc. forming a bottoming baseQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating - AInvest
Using Ichimoku Cloud for Editas Medicine Inc. technicalsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Editas Medicine Inc. stock ready for a breakoutJuly 2025 Big Picture & Smart Investment Allocation Tips - Newser
Real time scanner hits for Editas Medicine Inc. explainedMarket Weekly Review & Low Drawdown Trading Techniques - Newser
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
How to escape a deep drawdown in Editas Medicine Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.10 Consensus Target Price from Analysts - MarketBeat
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience - Investing.com
Can volume confirm reversal in Editas Medicine Inc.Quarterly Earnings Report & Free Fast Gain Swing Trade Alerts - Newser
Using data models to predict Editas Medicine Inc. stock movementPortfolio Return Report & Low Risk High Reward Trade Ideas - Newser
Is Editas Medicine Inc. stock entering bullish territoryPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Recession Risk & AI Forecast Swing Trade Picks - Newser
Is Editas Medicine Inc. showing signs of accumulation2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Evaluating Editas Medicine Inc. with trendline analysisQuarterly Profit Summary & Consistent Growth Stock Picks - Newser
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $4 to $4 - 富途牛牛
Editas Medicine price target raised to $4 from $3 at Wells Fargo - TipRanks
Editas Medicine at Wells Fargo Conference: Gene Editing Milestone - Investing.com
Activity Recap: How does Editas Medicine Inc. score in quality rankingsDay Trade & Free Accurate Trade Setup Notifications - خودرو بانک
what the charts say about editas medicine inc. todayQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
Is now the right time to enter Editas Medicine Inc.Dividend Hike & Low Drawdown Investment Ideas - خودرو بانک
How to track smart money flows in Editas Medicine Inc.Weekly Trade Review & Verified Technical Signals - Newser
Is it time to cut losses on Editas Medicine Inc.2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - Yahoo Finance
Is Editas Medicine Inc. forming a reversal patternTrade Volume Summary & Weekly Stock Breakout Alerts - Newser
What machine learning models say about Editas Medicine Inc.Weekly Stock Report & High Accuracy Swing Trade Signals - Newser
Can Editas Medicine Inc. grow without external fundingJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - خودرو بانک
Editas Medicine’s Strategic Milestone in In Vivo Gene Editing: A Catalyst for Long-Term Value - AInvest
Chart based exit strategy for Editas Medicine Inc.Swing Trade & Reliable Trade Execution Plans - Newser
Macro Review: Is Editas Medicine Inc.’s ROE strong enoughWeekly Profit Report & Growth Oriented Trading Recommendations - خودرو بانک
Applying big data sentiment scoring on Editas Medicine Inc.Earnings Beat & Intraday High Probability Alerts - Newser
Does Editas Medicine Inc. stock have upside surprise potentialTrade Performance Summary & Daily Growth Stock Investment Tips - خودرو بانک
When is the best time to exit Editas Medicine Inc.Quarterly Growth Report & Daily Entry Point Alerts - Newser
Editas Medicine shares rise 1.30% after-hours after unveiling lead development candidate EDIT-401. - AInvest
Editas Medicine shares fall 1.75% intraday after announcing EDIT-401 as lead in vivo development candidate. - AInvest
What the charts say about Editas Medicine Inc. today2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
1.40%
자본화:
|
볼륨(24시간):